Biotechnology Healthcare - June 2008 - (Page 63) INDEX Are We There Yet? Seeking the Value of Pharmacogenetics in Cardiovascular Care. Feb.: 61–62 A Drop of Blood To Nip Disease in the Bud. April: 11–14 MAYA-II and Molecular Computing. Oct.: 10–11 Infusion Clinics Business Savvy in the Age of Biologics. Aug.: 49–52 Medicare and Medicaid BIO: Part D Drug Costs Show the Market Works. April: 60 Molecular Diagnostics Molecular Imaging Modernizes Medicine. Feb.: 11–12 Cheap and Easy Cancer Diagnosis? Aug.: 14–15 Biogenetic Tests Emerge From Their Chrysalis. Oct.: 37–44 A Wish List for Molecular Tests. Dec.: 46–53 Patents Patent Pending: Biotech Awaits Answers on New Trends. Aug.: 57–60 Patient Health Information Making a RHIOlistic Effort To Improve Quality of Care. Aug.: 23–24 Pharmacoeconomics Demonstrating the Value of Biologics: A Call to Action. Aug.: 33–42 Pricing What Do Payers Really Want To See? April: 43–46 Regulation FDA Proposes Guidelines for Access to Experimental Therapies. Feb.: 9–10 The Unpredictable Path From Group to Individual Policies. April: 8–10 PDUFA Faces Rough Reauthorization. June: 9–10 Phase 4 Research Grows Despite FDA Enforcement. Oct.: 16, 22 Reimbursement Payment Issues Stunt Markets for Crohn’s and Psoriasis Therapies. April: 22 The Arrival of Average Sales Price. June: 48–53 Specialty Pharmacy Learning To Love Your Specialty Pharmacy. Oct.: 45–48 Specialty Drugs Continue To Drive Spending Growth. Oct.: 59 Stem Cell Research The World of Stem Cell Therapy: Anonymity Is Not an Option. June: 54–58 Technology Assessments Health Technology Assessment in Canada and the United States: The Case of Biologics. April: 47–51 Utilization Management New England Health Plan Relaxes Access to Omalizumab. Feb.: 22 PA No More? Aug.: 53–56 Venture Capital Where VC Fears To Tread. Oct.: 29–35 Small Investments, Big Payoffs. Oct.: 3 Some Predictions for 2008. Dec.: 4 Trends Biotech Proving a Formidable Provider to Pharma Innovation. Feb.: 68 BIO: Part D Drug Costs Show the Market Works. April: 60 Commercial Formularies Face Pressure To Go 4-Tier. June: 61 Specialty Drugs Continue To Drive Spending Growth. Oct.: 59 Additional Indications Drive Higher Specialty Spending. Dec.: 61 Washington Watch FDA Proposes Guidelines for Access to Experimental Therapies. Feb.: 9–10 The Unpredictable Path From Group to Individual Policies. April: 8–10 PDUFA Faces Rough Reauthorization. June: 9–10 Budgetary Battles Burden Trial Funding. Aug.: 10–11 Traversing the Landscape of Project BioShield. Oct.: 7–8 Money-Back Guarantees: Where Private Payers Might Not Wait for CMS To Lead. Dec.: 10–11 DEPARTMENTS Biotech Business New England Health Plan Relaxes Access to Omalizumab. Feb.: 22 Payment Issues Stunt Markets for Crohn’s and Psoriasis Therapies. April: 22 Debate on Follow-on Biologics Intensifies After Release of Report. June: 22 Making a RHIOlistic Effort To Improve Quality of Care. Aug.: 23–24 Phase 4 Research Grows Despite FDA Enforcement. Oct.: 16, 22 Employers Work To Manage Biologics in 2008 Benefit Designs. Dec.:20–21 Conference Coverage Making an Impression on Biotech Development. Dec.: 60 Corporate Spotlight Biologics Provide Hope for Immune System Disorders. Oct.: 55–58 Diagnostics and Devices Molecular Imaging Modernizes Medicine. Feb.: 11–12 A Drop of Blood To Nip Disease in the Bud. April: 11–14 ‘Natural Plastics’ Ripe With Potential. June: 11–12, 18 Cheap and Easy Cancer Diagnosis? Aug.: 14–15 MAYA-II and Molecular Computing. Oct.: 10–11 Ousting the “Ouch Factor” in Drug Delivery. Dec.: 15–16 DrugTrack Approvals, FDA Actions, Clinical Trials. Feb.: 14–15 April: 15–16 June: 19–20 Aug.: 16–17 Oct.: 14–15 Dec.: 17–18 Editorial by David B. Nash, MD, MBA Say What? Feb.: 6 MANA From Heaven. April: 6 Phone Home. June: 7 CMS Value-Based Purchasing. Aug.: 9 Choosing the Right Tool. Oct.: 6 The Biotech Detail Rep of the Future. Dec.: 9 Openers Everything Old Is New Again. Feb.: 3 Patience Is Bitter, Its Fruit Is Sweet. April: 3 In Search of a Better Way. June: 3 Nothing Generic About This Issue. Aug.: 3 SUPPLEMENTS TO BIOTECHNOLOGY HEALTHCARE TITLE OF SUPPLEMENT Managed Care Best Practices in Oncology Management. April. AUTHORS AND SPEAKERS Frame, Richard N. The Current Landscape of Oncology in Managed Care. April: 5–7 Gleeson, Jeremy M. Protocols and Working With Oncologists. April: 11–12 Harston, Dennis T. The Process of Care. April: 8–10 Jaramillo, Robert. Managing Oncology Agents: An HMO’s Perspective. April: 16–19 Mark, Joshua L; Pesko, Larry. Pharmacy and Cancer Care. April: 13–15 SUPPLEMENT TOPICS Clinical Practice Guidelines The Current Landscape of Oncology in Managed Care. April: 5–7 Protocols and Working With Oncologists. April: 11–12 Pharmaceutical Management Pharmacy and Cancer Care. April: 13–15 Managing Oncology Agents: An HMO’s Perspective. April: 16–19 Treatment Issues in Oncology Management. April: 2–4 The Process of Care. April: 8–10 MAY/JUNE 2008 · BIOTECHNOLOGY HEALTHCARE 63
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.